DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on April 8, 2005; DOI: 10.1124/dmd.104.002279

0090-9556/05/3307-1074-1081$20.00
DMD 33:1074-1081, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.104.002279v1
33/7/1074    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCune, J. S.
Right arrow Articles by Shen, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCune, J. S.
Right arrow Articles by Shen, D. D.

CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION

Jeannine S. McCune, Linda J. Risler, Brian R. Phillips, Kenneth E. Thummel, David Blough, and Danny D. Shen

Departments of Pharmacy (J.S.M., D.B., D.D.S.) and Pharmaceutics (K.E.T., D.D.S.), University of Washington, Seattle, Washington; and Clinical Pharmacokinetics Laboratory (J.S.M., L.J.R., B.R.P., D.D.S.), Fred Hutchinson Cancer Research Center, Seattle, Washington

Ifosfamide nephrotoxicity is attributed to the formation of a toxic metabolite, chloroacetaldehyde, via N-dechloroethylation, a reaction that is purportedly catalyzed by CYP3A and CYP2B6. Because allelic variants of CYP3A5 are associated with polymorphic expression of microsomal CYP3A5 in human liver and kidneys, we hypothesized that ifosfamide N-dechloroethylation depends on CYP3A5 genotype. We compared ifosfamide N-dechloroethylation activity in cDNA-expressed CYP3A4 and CYP3A5. Ifosfamide N-dechloroethylation was also assessed in liver (N = 20) and kidney (N = 21) microsomes from human donors with different CYP3A5 genotypes. Ifosfamide N-dechloroethylation was catalyzed by recombinant CYP3A5 at a rate comparable with recombinant CYP3A4. In human liver microsomes matched for CYP3A4 protein content, N-dechloroethylation was more than 2-fold higher in that from donors carrying CYP3A5*1 allele that express CYP3A5 relative to that from donors homozygous for the mutant CYP3A5*3. Correlation analysis revealed that ifosfamide N-dechloroethylation was significantly associated with CYP3A4 and CYP3A5 protein concentration but not with age, sex, or CYP2B6 protein concentration. In hepatic microsomes not expressing CYP3A5 protein, ifosfamide N-dechloroethylation was inhibited 53 to 61% and 0 to 3% by monoclonal antibodies specific for CYP3A4/5 or CYP2B6, respectively. Ifosfamide N-dechloroethylation was not detected in renal microsomes obtained from CYP3A5*3/*3 donors. In contrast, it was readily measurable in microsomes isolated from four kidneys of CYP3A5*1 carriers, which was almost completely inhibited by the CYP3A inhibitor ketoconazole. CYP2B6 protein could not be detected in this panel of human renal microsomes. In conclusion, CYP3A5*1 genotype is associated with higher rates of ifosfamide N-dechloroethylation in human liver and kidneys.

Address correspondence to: Dr. Jeannine S. McCune, Box 357630, University of Washington, Seattle, WA 98195. E-mail: jmccune{at}u.washington.edu




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
B. Ma, S. L. Polsky-Fisher, S. Vickers, D. Cui, and A. D. Rodrigues
Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective {gamma}-Aminobutyric AcidA{alpha}2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics
Drug Metab. Dispos., August 1, 2007; 35(8): 1301 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. B. Dennison, P. Kulanthaivel, R. J. Barbuch, J. L. Renbarger, W. J. Ehlhardt, and S. D. Hall
SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5
Drug Metab. Dispos., August 1, 2006; 34(8): 1317 - 1327.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.